European Thyroid Journal (Jan 2023)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer

  • Luciana Puleo,
  • Laura Agate,
  • Irene Bargellini,
  • Giuseppe Boni,
  • Paolo Piaggi,
  • Claudio Traino,
  • Tommaso Depalo,
  • Giulia Lorenzoni,
  • Francesca Bianchi,
  • Duccio Volterrani,
  • Sandra Brogioni,
  • Valeria Bottici,
  • Maurizia Rossana Brunetto,
  • Barbara Coco,
  • Eleonora Molinaro,
  • Rossella Elisei

DOI
https://doi.org/10.1530/ETJ-22-0130
Journal volume & issue
Vol. 11, no. 6
pp. 1 – 10

Abstract

Read online

Objectives: Liver metastases occur in 45% of patients with advanced metastatic medullary thyroid cancer (MTC). Transarterial radioembolization (TARE) has been proposed to treat liver metastases (LM), especially in neuroendocrine tumors. The aim of this study was to investigate the biochemical (calcitonin and carcino-embryonic antigen) and objective response of liver metastases from MTC to TARE. Methods: TARE is an internal radiotherapy in which microspheres loaded with β-emitting yttrium-90 (90Y) are delivered into the hepatic arteries that supply blood to LM. Eight patients with progressive multiple LM underwent TARE and were followed prospectively. They were clinically, biochemically and radiologically evaluated at 1, 4, 12 and 18 months after TARE. Results: Two patients were excluded from the analysis due to severe liver injury and death due to extrahepatic disease progression, respectively. One month after TARE, a statistically significant (P = 0.02) reduction of calcitonin was observed in all patients and remained clinically relevant during follow-up; reduction of CEA , although not significant, was found in all patients. Significant reduction of liver tumor mass was observed 1, 4 and 12 months after TARE (P = 0.007, P = 0.004, P = 0.002, respectively). After 1 month, three of six patients showed partial response (PR) and three of six stable disease (SD) according to RECIST 1.1, while five of six patients had a PR and one of six a SD according to mRECIST. The clinical response remained relevant 18 months after TARE. Excluding one patient, all others showed only a slight and transient increase in liver enzymes. Conclusions: TARE is effective in LM treatment of MTC. The absence of severe complications and the good tolerability make TARE a valid therapeutic strategy when liver LM are multiple and progressive.

Keywords